UKIPO rejects Novartis’s TM opposition attempt

Switzerland-based Novartis has failed to convince the UK Intellectual Property Office (IPO) that a trademark applied-for by Boston Healthcare should not be registered.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

article

UKIPO appoints permanent chief executive

13 December 2022 Interim CEO becomes permanent | Appointee “brings broad leadership experience and deep knowledge of the IPO” | Appointment “concludes a period of change at IPO”.

Big Pharma

Novartis sues Chinese firm over attempts to make generic heart failure drug

30 September 2021 Pharma giant Novartis has filed a patent suit against Crystal Pharmaceuticals after the rival sought to create a generic version of its heart failure drug Entresto.

Americas

Novartis and others in ‘unprecedented’ COVID-19 partnership

27 March 2020 A consortium of life sciences companies including Novartis, Bristol Myers Squibb and GSK have united to accelerate the development, manufacture and delivery of vaccines, diagnostics, and treatments for COVID-19.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

UKIPO rejects Novartis’s TM opposition attempt

More on this story

Editor's picks

Editor's picks

More features